GLPwatch
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Expert Rev Clin Pharmacol · 2016
Last updated 2026-05-28GLP-1 receptor agonists (GLP-1 RAs) are medications for type 2 diabetes that mimic a natural hormone to help control blood sugar, reduce appetite, and slow digestion. Clinical trials show these drugs lower blood sugar levels and help with weight loss in most cases, with side effects like nausea being common but low blood sugar being rare unless combined with other diabetes drugs. Future treatments may combine GLP-1 RAs with insulin.
AI summary of the abstract below.
| Journal | Expert Rev Clin Pharmacol, 2016 |
|---|---|
| Citations | 26 |
| Relative citation ratio | 0.94 |
| NIH percentile | 48 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.
Verbatim abstract via PubMed 26573176 ↗